Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

1.

Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.

Haas M, Laubender RP, Stieber P, Holdenrieder S, Bruns CJ, Wilkowski R, Mansmann U, Heinemann V, Boeck S.

Tumour Biol. 2010 Aug;31(4):351-7. doi: 10.1007/s13277-010-0044-6. Epub 2010 May 18.

PMID:
20480409
[PubMed - indexed for MEDLINE]
2.

Options for the treatment of gemcitabine-resistant advanced pancreatic cancer.

Gounaris I, Zaki K, Corrie P.

JOP. 2010 Mar 5;11(2):113-23. Review.

PMID:
20208317
[PubMed - indexed for MEDLINE]
Free Article
3.

Estimates of cancer incidence and mortality in Europe in 2008.

Ferlay J, Parkin DM, Steliarova-Foucher E.

Eur J Cancer. 2010 Mar;46(4):765-81. doi: 10.1016/j.ejca.2009.12.014. Epub 2010 Jan 29.

PMID:
20116997
[PubMed - indexed for MEDLINE]
4.

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.

Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP.

J Clin Oncol. 2009 Nov 20;27(33):5513-8. doi: 10.1200/JCO.2009.24.2446. Epub 2009 Oct 26.

PMID:
19858379
[PubMed - indexed for MEDLINE]
Free Article
5.

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ.

J Clin Oncol. 2009 May 1;27(13):2231-7. doi: 10.1200/JCO.2008.20.0238. Epub 2009 Mar 23.

PMID:
19307500
[PubMed - indexed for MEDLINE]
Free Article
6.

Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704.

Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB 3rd, MacDonald J, Willett CG.

J Clin Oncol. 2008 Dec 20;26(36):5918-22. doi: 10.1200/JCO.2008.18.6288. Epub 2008 Nov 24.

PMID:
19029412
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent.

Hernandez JM, Cowgill SM, Al-Saadi S, Collins A, Ross SB, Cooper J, Villadolid D, Zervos E, Rosemurgy A.

J Gastrointest Surg. 2009 Feb;13(2):349-53. doi: 10.1007/s11605-008-0696-3. Epub 2008 Oct 30.

PMID:
18972170
[PubMed - indexed for MEDLINE]
8.

CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer.

Nakai Y, Kawabe T, Isayama H, Sasaki T, Yagioka H, Yashima Y, Kogure H, Arizumi T, Togawa O, Ito Y, Matsubara S, Hirano K, Sasahira N, Tsujino T, Tada M, Omata M.

Oncology. 2008;75(1-2):120-6. doi: 10.1159/000155213. Epub 2008 Sep 11.

PMID:
18784438
[PubMed - indexed for MEDLINE]
9.

CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy.

Koom WS, Seong J, Kim YB, Pyun HO, Song SY.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1148-54. doi: 10.1016/j.ijrobp.2008.06.1483. Epub 2008 Aug 28.

PMID:
18760544
[PubMed - indexed for MEDLINE]
10.

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.

Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA.

Cancer. 2008 Oct 15;113(8):2046-52. doi: 10.1002/cncr.23810.

PMID:
18756532
[PubMed - indexed for MEDLINE]
Free Article
11.

Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.

Maréchal R, Demols A, Gay F, De Maertelaere V, Arvanitaki M, Hendlisz A, Van Laethem JL.

Oncology. 2007;73(1-2):41-51. doi: 10.1159/000120627. Epub 2008 Mar 11.

PMID:
18334830
[PubMed - indexed for MEDLINE]
12.
13.

Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.

Boeck S, Heinemann V.

J Clin Oncol. 2008 Mar 1;26(7):1178-9; author reply 1179. doi: 10.1200/JCO.2007.15.3304. No abstract available.

PMID:
18309957
[PubMed - indexed for MEDLINE]
Free Article
14.

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group.

J Clin Oncol. 2007 Jun 1;25(16):2212-7.

PMID:
17538165
[PubMed - indexed for MEDLINE]
Free Article
15.

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23.

PMID:
17452677
[PubMed - indexed for MEDLINE]
Free Article
16.

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM.

J Clin Oncol. 2006 Sep 20;24(27):4441-7.

PMID:
16983112
[PubMed - indexed for MEDLINE]
Free Article
17.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.

J Clin Oncol. 2006 Aug 20;24(24):3946-52.

PMID:
16921047
[PubMed - indexed for MEDLINE]
Free Article
18.

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V.

Br J Cancer. 2006 Sep 4;95(5):587-92. Epub 2006 Aug 8.

PMID:
16909140
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.

Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D.

Br J Cancer. 2005 Oct 3;93(7):740-3.

PMID:
16175188
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL.

Ann Oncol. 2005 Oct;16(10):1639-45. Epub 2005 Aug 8. Erratum in: Ann Oncol. 2006 Mar;17(3):535.

PMID:
16087696
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk